Difference between revisions of "Ramosetron (Iribo)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== Serotonin 5HT3 receptor antagonist with antiemetic properties. No known antineoplastic properties. ==History of FDA approval== Not FDA-approved; avail...") |
m |
||
(3 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
− | Serotonin | + | Serotonin 5-HT3 receptor antagonist with antiemetic properties. No known antineoplastic properties. Not FDA-approved; available in Japan and Southeast Asia. |
− | |||
− | |||
− | Not FDA-approved; available in Japan and Southeast Asia. | ||
==Also known as== | ==Also known as== | ||
− | IBset, Nasea, Nozia | + | *'''Brand names:''' IBset, Iribo, Irribow, Nasea, Nozia |
− | [[Category: | + | [[Category:Drugs]] |
+ | [[Category:Oral medications]] | ||
+ | [[Category:Intravenous medications]] | ||
[[Category:Emesis prevention]] | [[Category:Emesis prevention]] | ||
[[Category:Serotonin 5-HT3 antagonists]] | [[Category:Serotonin 5-HT3 antagonists]] | ||
+ | [[Category:PMDA approved in 2015]] |
Latest revision as of 01:27, 11 June 2023
Mechanism of action
Serotonin 5-HT3 receptor antagonist with antiemetic properties. No known antineoplastic properties. Not FDA-approved; available in Japan and Southeast Asia.
Also known as
- Brand names: IBset, Iribo, Irribow, Nasea, Nozia